The company said that it plans to use funds from its recent $18 million Series B round to drive instrument sales and develop AI tools for data analysis.
Investors included Bruker, whose MALDI mass spectrometry imaging platforms could have synergies with Ionpath's Multiplexed Ion Beam Imaging technology.
The new company will use Seer's Proteograph proteomic platform along with other omics data to develop and commercialize tests for cancer and other diseases.
Canopy offers products and services for gene editing, gene expression analysis and regulation, and bioprocessing, as well as a multi-omic immune profiling platform.
Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.
Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.
